Rallybio (NASDAQ:RLYB) Major Shareholder Buys $700,000.00 in Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 50,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $700,000.00. Following the purchase, the insider directly owned 829,784 shares in the company, valued at approximately $11,616,976. The trade was a 6.41% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The shares were acquired at an average price of $13.83 per share, for a total transaction of $11,064.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The shares were acquired at an average price of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Stock Performance

Shares of Rallybio stock traded up $0.32 on Wednesday, hitting $14.35. 150,607 shares of the company’s stock were exchanged, compared to its average volume of 633,223. The company has a 50-day simple moving average of $9.70 and a 200-day simple moving average of $6.93. The stock has a market capitalization of $75.91 million, a PE ratio of -5.61 and a beta of -1.10. Rallybio Corporation has a 1 year low of $2.16 and a 1 year high of $15.31.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.23 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.

Analyst Ratings Changes

Several brokerages have recently weighed in on RLYB. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Rallybio

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares in the last quarter. Susquehanna International Group LLP lifted its stake in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares in the last quarter. Citadel Advisors LLC lifted its stake in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.